Meeting
2018 ASCO Annual Meeting
Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study.
Authors
Michelle A. Fanale
The University of Texas MD Anderson Cancer Center, Houston, TX
Michelle A. Fanale , Paul A. Hamlin , Steven I. Park , Daniel Oscar Persky , Jack P. Higgins , Christine Burnett , Kristina Dabovic , Eric Poma , Nenad Sarapa , Anas Younes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT02361346
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7580)
DOI
10.1200/JCO.2018.36.15_suppl.7580
Abstract #
7580
Poster Bd #
217
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.
First Author: Erel Joffe
Poster
2020 ASCO Virtual Scientific Program
Efficacy and safety of ABP 798 compared with rituximab: Results from the comparative clinical study in patients with non-Hodgkin’s.
First Author: Dietger Niederwieser
Poster
2020 ASCO Virtual Scientific Program
A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma.
First Author: Adolfo Enrique Diaz Duque